ArticleAnnals of medicine and surgery (2012)2025
Isolated high-altitude cerebral edema in the Himalayas: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: High-altitude cerebral edema (HACE) is the cerebral form of high-altitude sickness. It is a rare life-threatening condition that has been reported in 0.1-2% at altitudes above 3000 to 4000 m. Case presentation: In this case, the authors have presented a 47-year-old male who was rescued from the Everest Region of Nepal at an altitude of 4900 after complaining of a severe headache, followed by an episode of vomiting, along with confusion and inability to walk on his own. He was treated with dexamethasone and other supportive measures in the emergency department. Magnetic resonance imaging (MRI) findings were suggestive of HACE. The patient was subsequently admitted for observation and neurological consultation. Discussion: HACE can occur as a sequela of acute mountain sickness (AMS), concurrently with high-altitude pulmonary edema (HAPE), or in isolated form. The exact pathophysiology of HACE remains incompletely understood. Clinical features include severe headache, vomiting, dizziness, loss of consciousness, drowsiness, ataxia, and eventually lead to coma. MRI is the investigation of choice. Management includes immediate descent, supplemental oxygen, dexamethasone, and hyperbaric therapy. Conclusion: HACE has an unpredictable course, as it can progress rapidly. Proper acclimatization and taking appropriate precautions are essential when ascending to high altitudes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.